Business
OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit
Clinical data from Phase 1b prostate cancer trial to be released in Q4/25Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma to be released on October 10, 2025New York, New York--(Newsfile Corp. - September 12, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody..
About this update from Os Therapies Incorporated
[{"type":"list","items":[{"val":[{"type":"text","content":"Clinical data from Phase 1b prostate cancer trial to be released in Q4/25","length":73,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Additionally, updated 2-year overall survival data from all 40 patients in the Phase 2b clinical trial of OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma to be released on October 10, 2025","length":240,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":313,"olType":false},{"type":"text","content":"New York, New York--(Newsfile Corp. - September 12, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that the last patient enrolled in its OST-504 (previously ADXS-504) Phase 1b clinical trial in subjects with biochemically recurrent prostate cancer previously treated with radical prostatectomy (RP) or radiation therapy (external beam or brachytherapy) who are not currently receiving androgen ablation therapy has completed their last patient visit (NCT05077098). A total of 7 patients enrolled in the study.","length":670,"tagName":"p"},{"type":"text","content":""We were pleasantly surprised by the level of enthusiasm around the OST-504 program from the clinical investigators at Columbia University after we took over the program as part of the acquisition of assets from Ayala," said Robert Petit, PhD, Chief Medical & Scientific Officer at OS Therapies. "We were especially excited that there was significant demand for expanded access following treatment. We believe the OST-504 construct has significant potential to be used in various prostate cancer settings and look forward to reporting on the study results in the fourth quarter of 2025."","length":611,"tagName":"p"},{"type":"text","content":""While we remain extremely focused on the regulatory pathway for OST-HER2 in osteosarcoma where we are preparing to initiate a rolling submission for a Biologics Licensing Application (BLA) in the next several weeks, we are in the fortunate position of being able to read out on an important initial proof of concept study in a major clinical indication without having to spend any money treating patients," ...